{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T20:25:03Z","timestamp":1787603103052,"version":"build-2736575974"},"reference-count":202,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T00:00:00Z","timestamp":1728345600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>The most prevalent reason for vision impairment in aging inhabitants is age-related macular degeneration (AMD), a posterior ocular disease with a poor understanding of the anatomic, genetic, and pathophysiological progression of the disease. Recently, new insights exploring the role of atrophic changes in the retinal pigment epithelium, extracellular drusen deposits, lysosomal lipofuscin, and various genes have been investigated in the progression of AMD. Hence, this review explores the incidence and risk factors for AMD, such as oxidative stress, inflammation, the complement system, and the involvement of bioactive lipids and their role in angiogenesis. In addition to intravitreal anti-vascular endothelial growth factor (VEGF) therapy and other therapeutic interventions such as oral kinase inhibitors, photodynamic, gene, and antioxidant therapy, as well as their benefits and drawbacks as AMD treatment options, strategic drug delivery methods, including drug delivery routes with a focus on intravitreal pharmacokinetics, are investigated. Further, the recent advancements in nanoformulations such as polymeric and lipid nanocarriers, liposomes, etc., intended for ocular drug delivery with pros and cons are too summarized. Therefore, the purpose of this review is to give new researchers an understanding of AMD pathophysiology, with an emphasis on angiogenesis, inflammation, the function of bioactive lipids, and therapy options. Additionally, drug delivery options that focus on the development of drug delivery system(s) via several routes of delivery can aid in the advancement of therapeutic choices.<\/jats:p>","DOI":"10.3390\/medicina60101647","type":"journal-article","created":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T12:01:54Z","timestamp":1728388914000},"page":"1647","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Age-Related Macular Degeneration (AMD): Pathophysiology, Drug Targeting Approaches, and Recent Developments in Nanotherapeutics"],"prefix":"10.3390","volume":"60","author":[{"given":"Mahendra","family":"Singh","sequence":"first","affiliation":[{"name":"Department of Biotechnology, Institute of Biotechnology, School of Life and Applied Sciences, Yeungnam University, Gyeongsan 38541, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riyakshi","family":"Negi","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, School of Heath Sciences and Technology, UPES, Dehradun 246008, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Alka","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, School of Heath Sciences and Technology, UPES, Dehradun 246008, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3568-2358","authenticated-orcid":false,"given":"Ramachandran","family":"Vinayagam","sequence":"additional","affiliation":[{"name":"Department of Biotechnology, Institute of Biotechnology, School of Life and Applied Sciences, Yeungnam University, Gyeongsan 38541, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5216-5494","authenticated-orcid":false,"given":"Sang Gu","family":"Kang","sequence":"additional","affiliation":[{"name":"Department of Biotechnology, Institute of Biotechnology, School of Life and Applied Sciences, Yeungnam University, Gyeongsan 38541, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1286-4183","authenticated-orcid":false,"given":"Prashant","family":"Shukla","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, School of Heath Sciences and Technology, UPES, Dehradun 246008, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,10,8]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"3758","DOI":"10.1016\/j.cell.2023.08.003","article-title":"Biomarkers of aging for the identification and evaluation of longevity interventions","volume":"186","author":"Moqri","year":"2023","journal-title":"Cell"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Tartiere, A.G., Freije, J.M.P., and L\u00f3pez-Ot\u00edn, C. (2024). The hallmarks of aging as a conceptual framework for health and longevity research. Front. Aging, 5.","DOI":"10.3389\/fragi.2024.1334261"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s00391-024-02324-1","article-title":"Psychosocial and biological pathways to aging: The role(s) of the behavioral and social sciences in geroscience","volume":"57","author":"Gellert","year":"2024","journal-title":"Z. Fur Gerontol. Geriatr."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1136\/bjophthalmol-2019-314422","article-title":"Prevalence and incidence of age-related macular degeneration in Europe: A systematic review and meta-analysis","volume":"104","author":"Li","year":"2020","journal-title":"Br. J. Ophthalmol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1007\/s00417-022-05885-2","article-title":"Antiplatelet and anticoagulant therapy in patients with submacular hemorrhage caused by neovascular age-related macular degeneration","volume":"261","author":"Weber","year":"2023","journal-title":"Graefe\u2019s Arch. Clin. Exp. Ophthalmol."},{"key":"ref_6","first-page":"180","article-title":"World report on vision","volume":"214","author":"Tedros","year":"2019","journal-title":"World Health Organ"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Yin, J., Jiang, B., Zhao, T., Guo, X., Tan, Y., and Wang, Y. (2024). Trends in the global burden of vision loss among the older adults from 1990 to 2019. Front. Public Health, 12.","DOI":"10.3389\/fpubh.2024.1324141"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"143","DOI":"10.4068\/cmj.2023.59.3.143","article-title":"Mechanistic Insight into Age-Related Macular Degeneration (AMD): Anatomy, Epidemiology, Genetics, Pathogenesis, Prevention, Implications, and Treatment Strategies to Pace AMD Management","volume":"59","author":"Amini","year":"2023","journal-title":"Chonnam Med. J."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"e144","DOI":"10.1016\/S2214-109X(20)30489-7","article-title":"Causes of blindness and vision impairment in 2020 and trends over 30 years, and prevalence of avoidable blindness in relation to VISION 2020: The Right to Sight: An analysis for the Global Burden of Disease Study","volume":"9","author":"Steinmetz","year":"2021","journal-title":"Lancet Glob. Health"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1001\/jama.2023.26074","article-title":"Age-Related Macular Degeneration: A Review","volume":"331","author":"Fleckenstein","year":"2024","journal-title":"JAMA"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.exer.2018.09.023","article-title":"The impact of lipids, lipid oxidation, and inflammation on AMD, and the potential role of miRNAs on lipid metabolism in the RPE","volume":"181","author":"Jun","year":"2019","journal-title":"Exp. Eye Res."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1038\/s41433-020-0770-y","article-title":"Use of biomaterials for sustained delivery of anti-VEGF to treat retinal diseases","volume":"34","author":"Seah","year":"2020","journal-title":"Eye"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Khalili Pour, E., Bazvand, F., Iyer, S., Khojasteh, H., Roohipourmoallai, R., and Hajizadeh, F. (2023). Age-Related Macular Degeneration. Atlas of Ocular Optical Coherence Tomography, Springer.","DOI":"10.1007\/978-3-031-07410-3_2"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"118767","DOI":"10.1016\/j.ijpharm.2019.118767","article-title":"Intravitreal anti-VEGF drug delivery systems for age-related macular degeneration","volume":"573","author":"Aguiar","year":"2020","journal-title":"Int. J. Pharm."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/eye.2013.107","article-title":"Adverse events and complications associated with intravitreal injection of anti-VEGF agents: A review of literature","volume":"27","author":"Nguyen","year":"2013","journal-title":"Eye"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"4527","DOI":"10.1007\/s10792-023-02853-5","article-title":"Real-world evidence in the use of Bevacizumab in age-related macular degeneration (ArMD): A scoping review","volume":"43","author":"Ghule","year":"2023","journal-title":"Int. Ophthalmol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e330","DOI":"10.1111\/aos.14589","article-title":"Variations and trends in global disease burden of age-related macular degeneration: 1990\u20132017","volume":"99","author":"Zou","year":"2021","journal-title":"Acta Ophthalmol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/aos.15224","article-title":"Visual impairment due to age-related macular degeneration during 40 years in Finland and the impact of novel therapies","volume":"101","author":"Purola","year":"2023","journal-title":"Acta Ophthalmol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e106","DOI":"10.1016\/S2214-109X(13)70145-1","article-title":"Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: A systematic review and meta-analysis","volume":"2","author":"Wong","year":"2014","journal-title":"Lancet Glob. Health"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Xu, X., Wu, J., Yu, X., Tang, Y., Tang, X., and Shentu, X. (2020). Regional differences in the global burden of age-related macular degeneration. BMC Public Health, 20.","DOI":"10.1186\/s12889-020-8445-y"},{"key":"ref_21","first-page":"109","article-title":"Race, iris color, and age-related macular degeneration","volume":"98","author":"Frank","year":"2000","journal-title":"Trans. Am. Ophthalmol. Soc."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1016\/j.ophtha.2015.06.018","article-title":"Prevalence and incidence of exudative age-related macular degeneration in South Korea: A nationwide population-based study","volume":"122","author":"Park","year":"2015","journal-title":"Ophthalmology"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.gendis.2021.02.009","article-title":"Age-related macular degeneration: Epidemiology, genetics, pathophysiology, diagnosis, and targeted therapy","volume":"9","author":"Deng","year":"2022","journal-title":"Genes Dis."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Chakravarthy, U., Wong, T.Y., Fletcher, A., Piault, E., Evans, C., Zlateva, G., Buggage, R., Pleil, A., and Mitchell, P. (2010). Clinical risk factors for age-related macular degeneration: A systematic review and meta-analysis. BMC Ophthalmol., 10.","DOI":"10.1186\/1471-2415-10-31"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1016\/S0140-6736(22)02609-5","article-title":"Age-related macular degeneration","volume":"401","author":"Guymer","year":"2023","journal-title":"Lancet"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1001\/archopht.122.4.598","article-title":"Current concepts in the pathogenesis of age-related macular degeneration","volume":"122","author":"Zarbin","year":"2004","journal-title":"Arch. Ophthalmol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2322","DOI":"10.1016\/j.drudis.2022.04.013","article-title":"Novel and investigational therapies for wet and dry age-related macular degeneration","volume":"27","author":"Sarkar","year":"2022","journal-title":"Drug Discov. Today"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1076\/ceyr.25.2.79.10158","article-title":"Extracellular matrix ligands promote RPE attachment to inner Bruch\u2019s membrane","volume":"25","author":"Priore","year":"2002","journal-title":"Curr. Eye Res."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Serjanov, D., and Hyde, D.R. (2023). Extracellular Matrix: The Unexplored Aspects of Retinal Pathologies and Regeneration. Retinal Degenerative Diseases XIX: Mechanisms and Experimental Therapy, Springer.","DOI":"10.1007\/978-3-031-27681-1_45"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"107867","DOI":"10.1016\/j.exer.2019.107867","article-title":"Oxidative stress in corneal injuries of different origin: Utilization of 3D human corneal epithelial tissue model","volume":"190","author":"Kaluzhny","year":"2020","journal-title":"Exp. Eye Res."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"e18069","DOI":"10.1111\/jcmm.18069","article-title":"Differences in change of post-operative antioxidant levels between laser-assisted lenticule extraction and femtosecond laser in situ keratomileusis","volume":"28","author":"Chen","year":"2023","journal-title":"J. Cell. Mol. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s12177-011-9068-4","article-title":"RPE barrier breakdown in diabetic retinopathy: Seeing is believing","volume":"4","author":"Xu","year":"2011","journal-title":"J. Ocul. Biol. Dis. Inform."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"109469","DOI":"10.1016\/j.exer.2023.109469","article-title":"Establishment of specific age-related macular degeneration relevant gene expression panels using porcine retinal pigment epithelium for assessing fucoidan bioactivity","volume":"231","author":"Akkurt","year":"2023","journal-title":"Exp. Eye Res."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Kushwah, N., Bora, K., Maurya, M., Pavlovich, M.C., and Chen, J. (2023). Oxidative stress and antioxidants in age-related macular degeneration. Antioxidants, 12.","DOI":"10.3390\/antiox12071379"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"102066","DOI":"10.1016\/j.arr.2023.102066","article-title":"Glutathione and Glutathione-dependent Enzymes: From Biochemistry to Gerontology and Successful Aging","volume":"92","author":"Lapenna","year":"2023","journal-title":"Ageing Res. Rev."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"e2100122118","DOI":"10.1073\/pnas.2100122118","article-title":"Lipofuscin causes atypical necroptosis through lysosomal membrane permeabilization","volume":"118","author":"Pan","year":"2021","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"R\u00f3\u017canowska, M.B. (2023). Lipofuscin, its origin, properties, and contribution to retinal fluorescence as a potential biomarker of oxidative damage to the retina. Antioxidants, 12.","DOI":"10.20944\/preprints202307.0304.v1"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"7285","DOI":"10.1167\/iovs.14-15195","article-title":"Mice that produce ApoB100 lipoproteins in the RPE do not develop drusen yet are still a valuable experimental system","volume":"55","author":"Fujihara","year":"2014","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_39","first-page":"430","article-title":"Lipids, oxidized lipids, oxidation-specific epitopes, and Age-related Macular Degeneration","volume":"1862","author":"Handa","year":"2017","journal-title":"Biochim. Biophys. Acta BBA-Mol. Cell Biol. Lipids"},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Hadziahmetovic, M., and Malek, G. (2021). Age-related macular degeneration revisited: From pathology and cellular stress to potential therapies. Front. Cell Dev. Biol., 8.","DOI":"10.3389\/fcell.2020.612812"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.carbon.2022.09.045","article-title":"Anti-angiogenic carbon nanovesicles loaded with bevacizumab for the treatment of age-related macular degeneration","volume":"201","author":"Anand","year":"2023","journal-title":"Carbon"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/febs.16278","article-title":"Role of inflammasome activation in neovascular age-related macular degeneration","volume":"290","author":"Marneros","year":"2023","journal-title":"FEBS J."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1080\/02713683.2023.2259634","article-title":"Honokiol Attenuates Choroidal Neovascularization by Inhibiting the Hypoxia-inducible Factor-\u03b1\/Vascular Endothelial Growth Factor Axis via Nuclear transcription factor-kappa B Activation","volume":"49","author":"Pan","year":"2023","journal-title":"Curr. Eye Res."},{"key":"ref_44","unstructured":"Kiernan, D.F. (2012). Stopping Dry-to-Wet AMD Conversion. Ophthalmol. Manag., 59\u201364. Available online: https:\/\/ophthalmologymanagement.com\/issues\/2012\/november\/stopping-dry-to-wet-amd-conversion\/."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.ophtha.2016.10.010","article-title":"Dual antagonism of PDGF and VEGF in neovascular age-related macular degeneration: A phase IIb, multicenter, randomized controlled trial","volume":"124","author":"Jaffe","year":"2017","journal-title":"Ophthalmology"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"e19503","DOI":"10.1016\/j.heliyon.2023.e19503","article-title":"LncRNA MALAT1 knockdown inhibits the development of choroidal neovascularization","volume":"9","author":"Zhang","year":"2023","journal-title":"Heliyon"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.15252\/embj.201591881","article-title":"Complement activation, regulation, and molecular basis for complement-related diseases","volume":"34","author":"Bajic","year":"2015","journal-title":"EMBO J."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Merle, N.S., Church, S.E., Fremeaux-Bacchi, V., and Roumenina, L.T. (2015). Complement system part I\u2014Molecular mechanisms of activation and regulation. Front. Immunol., 6.","DOI":"10.3389\/fimmu.2015.00262"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1111\/joim.12338","article-title":"Complement regulators in human disease: Lessons from modern genetics","volume":"277","author":"Liszewski","year":"2015","journal-title":"J. Intern. Med."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"e3590","DOI":"10.1002\/jgm.3590","article-title":"Bioinformatics-based analysis of programmed cell death pathway and key prognostic genes in gastric cancer: Implications for the development of therapeutics","volume":"26","author":"Huang","year":"2024","journal-title":"J. Gene Med."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.jconrel.2023.11.035","article-title":"Extracellular vesicles in degenerative retinal diseases: A new therapeutic paradigm","volume":"365","author":"Manai","year":"2024","journal-title":"J. Control. Release"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"4487","DOI":"10.1007\/s00018-021-03796-9","article-title":"The complement system in age-related macular degeneration","volume":"78","author":"Armento","year":"2021","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1080\/14656566.2023.2257604","article-title":"The complement system: A novel therapeutic target for age-related macular degeneration","volume":"24","author":"Shughoury","year":"2023","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1038\/s41467-020-14499-3","article-title":"Increased circulating levels of Factor H-Related Protein 4 are strongly associated with age-related macular degeneration","volume":"11","author":"Cipriani","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"3142","DOI":"10.1016\/j.ajpath.2014.07.017","article-title":"The membrane attack complex in aging human choriocapillaris: Relationship to macular degeneration and choroidal thinning","volume":"184","author":"Mullins","year":"2014","journal-title":"Am. J. Pathol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"109770","DOI":"10.1016\/j.exer.2023.109770","article-title":"Role of immune inflammation regulated by macrophage in the pathogenesis of age-related macular degeneration","volume":"239","author":"Zhao","year":"2023","journal-title":"Exp. Eye Res."},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Papp, A., Papp, K., Uzonyi, B., Cserhalmi, M., Csincsi, \u00c1.I., Szab\u00f3, Z., B\u00e1nlaki, Z., Ermert, D., Proh\u00e1szka, Z., and Erdei, A. (2022). Complement Factor H-related proteins FHR1 and FHR5 interact with extracellular matrix ligands, reduce Factor H regulatory activity and enhance complement activation. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.845953"},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Swinkels, M., Zhang, J.H., Tilakaratna, V., Black, G., Perveen, R., McHarg, S., Inforzato, A., Day, A.J., and Clark, S.J. (2018). C-reactive protein and pentraxin-3 binding of factor H-like protein 1 differs from complement factor H: Implications for retinal inflammation. Sci. Rep., 8.","DOI":"10.1038\/s41598-017-18395-7"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1056\/NEJMoa072618","article-title":"Complement C3 variant and the risk of age-related macular degeneration","volume":"357","author":"Yates","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"106417","DOI":"10.1016\/j.isci.2023.106417","article-title":"Ultra-rare complement factor 8 coding variants in families with age-related macular degeneration","volume":"26","author":"Zelinger","year":"2023","journal-title":"iScience"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"5662","DOI":"10.1016\/j.clnu.2021.10.005","article-title":"Dietary omega-3 polyunsaturated fatty acids and fish intake and risk of age-related macular degeneration","volume":"40","author":"Jiang","year":"2021","journal-title":"Clin. Nutr."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/j.survophthal.2014.01.001","article-title":"The role of omega-3 and micronutrients in age-related macular degeneration","volume":"59","author":"Querques","year":"2014","journal-title":"Surv. Ophthalmol."},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Saxena, S., Singh, R., Dutta, D., Gautam, N., Setya, S., and Talegaonkar, S. (2024). Nutraceuticals and Their Applications: Recent Trends and Challenges. Anxiety Gut Microbiome Nutraceuticals, CRC Press.","DOI":"10.1201\/9781003333821-1"},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Duan, H., Song, W., Zhao, J., and Yan, W. (2023). Polyunsaturated Fatty Acids (PUFAs): Sources, Digestion, Absorption, Application and Their Potential Adjunctive Effects on Visual Fatigue. Nutrients, 15.","DOI":"10.3390\/nu15112633"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1038\/nm1591","article-title":"Increased dietary intake of \u03c9-3-polyunsaturated fatty acids reduces pathological retinal angiogenesis","volume":"13","author":"Connor","year":"2007","journal-title":"Nat. Med."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"109093","DOI":"10.1016\/j.steroids.2022.109093","article-title":"Cytoprotective activities of representative nutrients from the Mediterranean diet and of Mediterranean oils against 7-ketocholesterol-and 7\u03b2-hydroxycholesterol-induced cytotoxicity: Application to age-related diseases and civilization diseases","volume":"187","author":"Rezig","year":"2022","journal-title":"Steroids"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.exer.2014.09.009","article-title":"7-ketocholesterol accumulates in ocular tissues as a consequence of aging and is present in high levels in drusen","volume":"128","author":"Rodriguez","year":"2014","journal-title":"Exp. Eye Res."},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Pariente, A., P\u00e9rez-Sala, \u00c1., Ochoa, R., Bobadilla, M., Villanueva-Mart\u00ednez, \u00c1., Pel\u00e1ez, R., and Larr\u00e1yoz, I.M. (2023). Identification of 7-Ketocholesterol-Modulated Pathways and Sterculic Acid Protective Effect in Retinal Pigmented Epithelium Cells by Using Genome-Wide Transcriptomic Analysis. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24087459"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"107746","DOI":"10.1016\/j.exer.2019.107746","article-title":"Inflammatory and cell death mechanisms induced by 7-ketocholesterol in the retina. Implications for age-related macular degeneration","volume":"187","author":"Pariente","year":"2019","journal-title":"Exp. Eye Res."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1001\/archopht.1984.01040031330019","article-title":"Age-related macular degeneration and blindness due to neovascular maculopathy","volume":"102","author":"Ferris","year":"1984","journal-title":"Arch. Ophthalmol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1007\/s00417-023-06022-3","article-title":"Sequential structural and functional change in geographic atrophy on multimodal imaging in non-exudative age-related macular degeneration","volume":"261","author":"Lee","year":"2023","journal-title":"Graefe\u2019s Arch. Clin. Exp. Ophthalmol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1177\/11206721231212545","article-title":"Smaller-Incision new-generation implantable miniature telescope: Three-months follow-up study","volume":"34","author":"Savastano","year":"2024","journal-title":"Eur. J. Ophthalmol."},{"key":"ref_73","first-page":"2461","article-title":"Evaluating an automated machine learning model that predicts visual acuity outcomes in patients with neovascular age-related macular degeneration","volume":"260","author":"Abbas","year":"2022","journal-title":"Graefe\u2019s Arch. Clin. Exp. Ophthalmol."},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"ElSheikh, R.H., Chauhan, M.Z., and Sallam, A.B. (2022). Current and novel therapeutic approaches for treatment of neovascular age-related macular degeneration. Biomolecules, 12.","DOI":"10.3390\/biom12111629"},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Fabre, M., Mateo, L., Lamaa, D., Baillif, S., Pag\u00e8s, G., Demange, L., Ronco, C., and Benhida, R. (2022). Recent advances in age-related macular degeneration therapies. Molecules, 27.","DOI":"10.3390\/molecules27165089"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta22270","article-title":"Treatments for dry age-related macular degeneration and Stargardt disease: A systematic review","volume":"22","author":"Waugh","year":"2018","journal-title":"Health Technol. Assess."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"100779","DOI":"10.1016\/j.preteyeres.2019.100779","article-title":"Retinal stem cell transplantation: Balancing safety and potential","volume":"75","author":"Singh","year":"2020","journal-title":"Prog. Retin. Eye Res."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1097\/IAE.0000000000003655","article-title":"Transplantation of subretinal stem cell\u2013derived retinal pigment epithelium for stargardt disease: A Phase I Clinical Trial","volume":"43","author":"Fernandes","year":"2023","journal-title":"Retina"},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Mahla, R.S., Mukherjee, A.K., Amin, S., Jainarayanan, A., Mouroug-Anand, N., Nandakumar, A., and Prasad, A.D. (2024). Stem Cells Application in Eye Regeneration and Restoration of Vision. Handbook of Stem Cell Applications, Springer Nature.","DOI":"10.1007\/978-981-99-7119-0_65"},{"key":"ref_80","first-page":"459","article-title":"A systems genetics approach to revealing the Pdgfb molecular network of the retina","volume":"26","author":"Li","year":"2020","journal-title":"Mol. Vis."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"a017178","DOI":"10.1101\/cshperspect.a017178","article-title":"Clinical characteristics and current treatment of age-related macular degeneration","volume":"5","author":"Yonekawa","year":"2015","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/j.ophtha.2019.12.031","article-title":"Brolucizumab: Evolution through preclinical and clinical studies and the implications for the management of neovascular age-related macular degeneration","volume":"127","author":"Nguyen","year":"2020","journal-title":"Ophthalmology"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"e00723","DOI":"10.1002\/prp2.723","article-title":"Biological drug therapy for ocular angiogenesis: Anti-VEGF agents and novel strategies based on nanotechnology","volume":"9","author":"Formica","year":"2021","journal-title":"Pharmacol. Res. Perspect."},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"Alfonso, H.G.A., Paz, M.C., Palma, S.D., and Formica, M.L. (2023). Advances in nanotechnology-based anti-VEGF agents for the management of ocular angiogenesis. Nanotechnology in Ophthalmology, Elsevier.","DOI":"10.1016\/B978-0-443-15264-1.00012-9"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1186\/s12967-023-03937-7","article-title":"Emerging therapeutic strategies for unmet need in neovascular age-related macular degeneration","volume":"21","author":"Khachigian","year":"2023","journal-title":"J. Transl. Med."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"905","DOI":"10.2147\/JEP.S259298","article-title":"Current and future anti-VEGF agents for neovascular age-related macular degeneration","volume":"13","author":"Kaiser","year":"2021","journal-title":"J. Exp. Pharmacol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.2147\/IJN.S105016","article-title":"Ethosomal nanocarriers: The impact of constituents and formulation techniques on ethosomal properties, in vivo studies, and clinical trials","volume":"11","author":"Abdulbaqi","year":"2016","journal-title":"Int. J. Nanomed."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"eabj2177","DOI":"10.1126\/scitranslmed.abj2177","article-title":"Targeting C3b\/C4b and VEGF with a bispecific fusion protein optimized for neovascular age-related macular degeneration therapy","volume":"14","author":"Yang","year":"2022","journal-title":"Sci. Transl. Med."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1001\/jamaophthalmol.2017.1571","article-title":"Oral tyrosine kinase inhibitor for neovascular age-related macular degeneration: A phase 1 dose-escalation study","volume":"135","author":"Jackson","year":"2017","journal-title":"JAMA Ophthalmol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1136\/bjophthalmol-2020-316511","article-title":"APEX: A phase II randomised clinical trial evaluating the safety and preliminary efficacy of oral X-82 to treat exudative age-related macular degeneration","volume":"105","author":"Cohen","year":"2021","journal-title":"Br. J. Ophthalmol."},{"key":"ref_91","doi-asserted-by":"crossref","unstructured":"Mohamed, J.M.M., Ahmad, F., El-Sherbiny, M., Padhare, S., and Khan, S. (2023). Nanocarriers: The enhanced potential treatment of age-related macular degeneration. Nanotechnology Principles in Drug Targeting and Diagnosis, Elsevier.","DOI":"10.1016\/B978-0-323-91763-6.00018-7"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1007\/s00417-005-0199-9","article-title":"Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: 5-year results of two randomized clinical trials with an open-label extension: TAP report no. 8","volume":"244","author":"Kaiser","year":"2006","journal-title":"Graefe\u2019s Arch. Clin. Exp. Ophthalmol."},{"key":"ref_93","doi-asserted-by":"crossref","unstructured":"Sterling, C., M\u00e1rquez-Garb\u00e1n, D., Vadgama, J.V., and Pietras, R.J. (2022). Squalamines in Blockade of Tumor-Associated Angiogenesis and Cancer Progression. Cancers, 14.","DOI":"10.3390\/cancers14205154"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/j.omtn.2019.07.018","article-title":"Anti-angiogenic and anti-scarring dual action of an anti-fibroblast growth factor 2 aptamer in animal models of retinal disease","volume":"17","author":"Matsuda","year":"2019","journal-title":"Mol. Ther.-Nucleic Acids"},{"key":"ref_95","doi-asserted-by":"crossref","unstructured":"Nakamura, Y. (2021). Multiple therapeutic applications of RBM-007, an anti-FGF2 aptamer. Cells, 10.","DOI":"10.3390\/cells10071617"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1038\/s41433-023-02849-6","article-title":"Safety and tolerability of intravitreal umedaptanib pegol (anti-FGF2) for neovascular age-related macular degeneration (nAMD): A phase 1, open-label study","volume":"38","author":"Pereira","year":"2023","journal-title":"Eye"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.2174\/1386207325666220501170846","article-title":"Current Status and Challenges of Aptamers Screening and Optimization","volume":"26","author":"Tan","year":"2023","journal-title":"Comb. Chem. High Throughput Screen."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1038\/s41433-021-01842-1","article-title":"Review of gene therapies for age-related macular degeneration","volume":"36","author":"Khanani","year":"2022","journal-title":"Eye"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/s41576-019-0205-4","article-title":"Engineering adeno-associated virus vectors for gene therapy","volume":"21","author":"Li","year":"2020","journal-title":"Nat. Rev. Genet."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/s41573-019-0012-9","article-title":"Adeno-associated virus vector as a platform for gene therapy delivery","volume":"18","author":"Wang","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_101","doi-asserted-by":"crossref","unstructured":"Blasiak, J., and Pawlowska, E. (2024). A New Generation of Gene Therapies as the Future of Wet AMD Treatment. IJMS, 25.","DOI":"10.20944\/preprints202401.1524.v1"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1167\/tvst.10.1.34","article-title":"Long-term safety evaluation of continuous intraocular delivery of aflibercept by the intravitreal gene therapy candidate ADVM-022 in nonhuman primates","volume":"10","author":"Kiss","year":"2021","journal-title":"Transl. Vis. Sci. Technol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"193","DOI":"10.52155\/ijpsat.v40.2.5623","article-title":"Ocular Gene Therapy","volume":"40","author":"Naser","year":"2023","journal-title":"Int. J. Progress. Sci. Technol. (IJPSAT)"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1111\/ceo.14294","article-title":"Treatment of dry age-related macular degeneration: A review","volume":"51","author":"Girgis","year":"2023","journal-title":"Clin. Exp. Ophthalmol."},{"key":"ref_105","doi-asserted-by":"crossref","unstructured":"Csader, S., Korhonen, S., Kaarniranta, K., and Schwab, U. (2022). The effect of dietary supplementations on delaying the progression of age-related macular degeneration: A systematic review and meta-analysis. Nutrients, 14.","DOI":"10.3390\/nu14204273"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/j.1755-3768.2011.02357.x","article-title":"Lifestyle modification, nutritional and vitamins supplements for age-related macular degeneration","volume":"91","author":"Sin","year":"2013","journal-title":"Acta Ophthalmol."},{"key":"ref_107","first-page":"297","article-title":"Treatments for dry age-related macular degeneration: Therapeutic avenues, clinical trials and future directions","volume":"106","author":"Varela","year":"2021","journal-title":"Br. J. Ophthalmol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"108513","DOI":"10.1016\/j.neuropharm.2021.108513","article-title":"New insights into oxidative stress and immune mechanisms involved in age-related macular degeneration tackled by novel therapies","volume":"188","author":"Potilinski","year":"2021","journal-title":"Neuropharmacology"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1007\/s00417-001-0398-y","article-title":"Inhibitory effects of triamcinolone acetonide on bFGF-induced migration and tube formation in choroidal microvascular endothelial cells","volume":"240","author":"Wang","year":"2002","journal-title":"Graefe\u2019s Arch. Clin. Exp. Ophthalmol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"36","DOI":"10.3129\/i09-243","article-title":"Triple therapy for neovascular age-related macular degeneration (verteporfin photodynamic therapy, intravitreal dexamethasone, and intravitreal bevacizumab)","volume":"45","author":"Ehmann","year":"2010","journal-title":"Can. J. Ophthalmol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1038\/sj.eye.6701438","article-title":"Exudative age-related macular degeneration treated by intravitreal triamcinolone acetonide. A prospective comparative nonrandomized study","volume":"19","author":"Jonas","year":"2005","journal-title":"Eye"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/eye.2010.196","article-title":"The role of anti-inflammatory agents in age-related macular degeneration (AMD) treatment","volume":"25","author":"Wang","year":"2011","journal-title":"Eye"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.survophthal.2019.07.001","article-title":"NSAID-induced corneal melt: Clinical importance, pathogenesis, and risk mitigation","volume":"65","author":"Rigas","year":"2020","journal-title":"Surv. Ophthalmol."},{"key":"ref_114","first-page":"657","article-title":"Intravitreal methotrexate","volume":"16","author":"Abdi","year":"2021","journal-title":"J. Ophthalmic Vis. Res."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/j.jconrel.2020.10.025","article-title":"Therapeutic nanoemulsions in ophthalmic drug administration: Concept in formulations and characterization techniques for ocular drug delivery","volume":"328","author":"Singh","year":"2020","journal-title":"J. Control. Release"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1208\/s12249-023-02516-9","article-title":"Ocular drug delivery: A comprehensive review","volume":"24","author":"Ahmed","year":"2023","journal-title":"AAPS PharmSciTech"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1615\/CritRevTherDrugCarrierSyst.2023045298","article-title":"Advanced Technologies of Drug Delivery to the Posterior Eye Segment Targeting Angiogenesis and Ocular Cancer","volume":"41","author":"Ansari","year":"2024","journal-title":"Crit. Rev. Ther. Drug Carr. Syst."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.jconrel.2014.06.043","article-title":"Ocular delivery of macromolecules","volume":"190","author":"Kim","year":"2014","journal-title":"J. Control. Release"},{"key":"ref_119","doi-asserted-by":"crossref","unstructured":"Wang, W., and Snider, N. (2023). Discovery and Potential Utility of a Novel Non-Invasive Ocular Delivery Platform. Pharmaceutics, 15.","DOI":"10.3390\/pharmaceutics15092344"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"122682","DOI":"10.1016\/j.ijpharm.2023.122682","article-title":"Pre-clinical safety of topically administered sunitinib-loaded lipid and polymeric nanocarriers targeting corneal neovascularization","volume":"635","author":"Souza","year":"2023","journal-title":"Int. J. Pharm."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.jconrel.2023.07.052","article-title":"Thermo-responsive Diels-Alder stabilized hydrogels for ocular drug delivery of a corticosteroid and an anti-VEGF fab fragment","volume":"361","author":"Ilochonwu","year":"2023","journal-title":"J. Control. Release"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1007\/s13346-016-0339-2","article-title":"A comprehensive insight on ocular pharmacokinetics","volume":"6","author":"Agrahari","year":"2016","journal-title":"Drug Deliv. Transl. Res."},{"key":"ref_123","doi-asserted-by":"crossref","unstructured":"Jang, M., Kang, M., Lee, E., and Shin, D. (2024). Ocular and Plasma Pharmacokinetics of Enavogliflozin Ophthalmic Solution in Preclinical Species. Pharmaceuticals, 17.","DOI":"10.3390\/ph17010111"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"5532","DOI":"10.1021\/acs.molpharmaceut.3c00415","article-title":"Fabrication of Chitosan\/PEGDA Bionanocomposites for Enhanced Drug Encapsulation and Release Efficiency","volume":"20","author":"Kandhola","year":"2023","journal-title":"Mol. Pharm."},{"key":"ref_125","doi-asserted-by":"crossref","unstructured":"Varela-Fern\u00e1ndez, R., D\u00edaz-Tom\u00e9, V., Luaces-Rodr\u00edguez, A., Conde-Penedo, A., Garc\u00eda-Otero, X., Luzardo-\u00c1lvarez, A., Fern\u00e1ndez-Ferreiro, A., and Otero-Espinar, F.J. (2020). Drug delivery to the posterior segment of the eye: Biopharmaceutic and pharmacokinetic considerations. Pharmaceutics, 12.","DOI":"10.3390\/pharmaceutics12030269"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"122453","DOI":"10.1016\/j.ijpharm.2022.122453","article-title":"Biodistribution of progesterone in the eye after topical ocular administration via drops or inserts","volume":"630","author":"Iglesias","year":"2023","journal-title":"Int. J. Pharm."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"2575","DOI":"10.1007\/s10792-023-02637-x","article-title":"Implantable sustained-release drug delivery systems: A revolution for ocular therapeutics","volume":"3","author":"Cong","year":"2023","journal-title":"Int. Ophthalmol."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s40005-023-00653-8","article-title":"Multicompartmental pharmacokinetic evaluation of enavogliflozin eye drop formulation: Understanding its distribution to posterior segments","volume":"54","author":"Cho","year":"2024","journal-title":"J. Pharm. Investig."},{"key":"ref_129","doi-asserted-by":"crossref","unstructured":"Garc\u00eda-Quintanilla, L., Luaces-Rodr\u00edguez, A., Gil-Mart\u00ednez, M., Mondelo-Garc\u00eda, C., Maro\u00f1as, O., Mangas-Sanjuan, V., Gonz\u00e1lez-Barcia, M., Zarra-Ferro, I., Aguiar, P., and Otero-Espinar, F.J. (2019). Pharmacokinetics of intravitreal anti-VEGF drugs in age-related macular degeneration. Pharmaceutics, 11.","DOI":"10.3390\/pharmaceutics11080365"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.preteyeres.2016.12.001","article-title":"Pharmacokinetic aspects of retinal drug delivery","volume":"57","author":"Heikkinen","year":"2017","journal-title":"Prog. Retin. Eye Res."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1517\/17425255.2013.796928","article-title":"Advances in the understanding of retinal drug disposition and the role of blood\u2013ocular barrier transporters","volume":"9","year":"2013","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"ref_132","doi-asserted-by":"crossref","unstructured":"Ramezani, P., De Smedt, S.C., and Sauvage, F. (2024). Supramolecular dye nanoassemblies for advanced diagnostics and therapies. Bioeng. Transl. Med., 9.","DOI":"10.1002\/btm2.10652"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"2827","DOI":"10.1167\/iovs.09-4172","article-title":"Blood\u2013retinal barrier glycerol permeability in diabetic macular edema and healthy eyes: Estimations from Macular Volume Changes after Peroral Glycerol","volume":"51","author":"Thornit","year":"2010","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1016\/j.bpj.2015.10.002","article-title":"Diffusion regulation in the vitreous humor","volume":"109","author":"Arends","year":"2015","journal-title":"Biophys. J."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"4807","DOI":"10.1167\/iovs.08-3148","article-title":"Pharmacokinetics of bevacizumab after topical, subconjunctival, and intravitreal administration in rabbits","volume":"50","author":"Nomoto","year":"2009","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_136","doi-asserted-by":"crossref","unstructured":"Spruill, M.L., Maletic-Savatic, M., Martin, H., Li, F., and Liu, X. (2022). Spatial analysis of drug absorption, distribution, metabolism, and toxicology using mass spectrometry imaging. Biochem. Pharmacol., 201.","DOI":"10.1016\/j.bcp.2022.115080"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.addr.2018.01.008","article-title":"Ocular delivery of proteins and peptides: Challenges and novel formulation approaches","volume":"126","author":"Mandal","year":"2018","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"120873","DOI":"10.1016\/j.ijpharm.2021.120873","article-title":"Colloidal nanosystems with mucoadhesive properties designed for ocular topical delivery","volume":"606","author":"Silva","year":"2021","journal-title":"Int. J. Pharm."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.addr.2017.12.017","article-title":"Ophthalmic gels: Past, present and future","volume":"126","author":"Zidan","year":"2018","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_140","doi-asserted-by":"crossref","unstructured":"Tsung, T.-H., Chen, Y.-H., and Lu, D.-W. (2023). Updates on Biodegradable Formulations for Ocular Drug Delivery. Pharmaceutics, 15.","DOI":"10.3390\/pharmaceutics15030734"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1016\/j.drudis.2021.02.027","article-title":"Advanced nanodelivery platforms for topical ophthalmic drug delivery","volume":"26","author":"Gholizadeh","year":"2021","journal-title":"Drug Discov. Today"},{"key":"ref_142","doi-asserted-by":"crossref","unstructured":"Akhter, M.H., Ahmad, I., Alshahrani, M.Y., Al-Harbi, A.I., Khalilullah, H., Afzal, O., Altamimi, A.S.A., Najib Ullah, S.N.M., Ojha, A., and Karim, S. (2022). Drug delivery challenges and current progress in nanocarrier-based ocular therapeutic system. Gels, 8.","DOI":"10.3390\/gels8020082"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1615\/CritRevTherDrugCarrierSyst.2023044057","article-title":"Current Insights into Targeting Strategies for the Effective Therapy of Diseases of the Posterior Eye Segment","volume":"41","author":"Pimple","year":"2024","journal-title":"Crit. Rev.\u2122 Ther. Drug Carr. Syst."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"27835","DOI":"10.1039\/D0RA04971A","article-title":"Nanocarriers for ocular drug delivery: Current status and translational opportunity","volume":"10","author":"Gorantla","year":"2020","journal-title":"RSC Adv."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.jconrel.2023.01.018","article-title":"Nanotechnology based drug delivery systems for the treatment of anterior segment eye diseases","volume":"354","author":"Onugwu","year":"2023","journal-title":"J. Control. Release"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"488","DOI":"10.2174\/1567201820666230504115446","article-title":"A Mini-review on New Developments in Nanocarriers and Polymers for Ophthalmic Drug Delivery Strategies","volume":"1","author":"Sharma","year":"2024","journal-title":"Curr. Drug Deliv."},{"key":"ref_147","doi-asserted-by":"crossref","unstructured":"Liu, L.-C., Chen, Y.-H., and Lu, D.-W. (2023). Overview of Recent Advances in Nano-Based Ocular Drug Delivery. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms242015352"},{"key":"ref_148","doi-asserted-by":"crossref","unstructured":"Li, S., Chen, L., and Fu, Y. (2023). Nanotechnology-based ocular drug delivery systems: Recent advances and future prospects. J. Nanobiotechnol., 21.","DOI":"10.1186\/s12951-023-01992-2"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1016\/j.jconrel.2020.10.054","article-title":"Nanodiagnostics and Nanotherapeutics for age-related macular degeneration","volume":"329","author":"Sarkar","year":"2021","journal-title":"J. Control. Release"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1080\/17425247.2024.2311119","article-title":"Recent advances in nanocrystal-based technologies applied for ocular drug delivery","volume":"21","author":"Geng","year":"2024","journal-title":"Expert Opin. Drug Deliv."},{"key":"ref_151","doi-asserted-by":"crossref","unstructured":"Mishra, A., Shaima, K.A., and Sindhu, R.K. (2024). Novel Drug Delivery System for Ocular Target. Nanotechnology and Drug Delivery, Jenny Stanford Publishing.","DOI":"10.1201\/9781003430407-6"},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2014\/161794","article-title":"Lipid nanoparticles as carriers for RNAi against viral infections: Current status and future perspectives","volume":"2014","author":"Torrecilla","year":"2014","journal-title":"BioMed Res. Int."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.addr.2009.11.026","article-title":"Chitosan-based nanostructures: A delivery platform for ocular therapeutics","volume":"62","author":"Paolicelli","year":"2010","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.jconrel.2015.01.030","article-title":"Coating nanocarriers with hyaluronic acid facilitates intravitreal drug delivery for retinal gene therapy","volume":"202","author":"Martens","year":"2015","journal-title":"J. Control. Release"},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1089\/jop.2010.0158","article-title":"Comparison of long-acting bevacizumab formulations in the treatment of choroidal neovascularization in a rat model","volume":"27","author":"Pan","year":"2011","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.jconrel.2019.01.007","article-title":"Long-acting intraocular Delivery strategies for biological therapy of age-related macular degeneration","volume":"296","author":"Iyer","year":"2019","journal-title":"J. Control. Release Off. J. Control. Release Soc."},{"key":"ref_157","first-page":"105489","article-title":"Recent theranostic paradigms for the management of Age-related macular degeneration","volume":"153","author":"Suri","year":"2020","journal-title":"Eur. J. Pharm. Sci. Off. J. Eur. Fed. Pharm. Sci."},{"key":"ref_158","doi-asserted-by":"crossref","unstructured":"Yang, B., Li, G., Liu, J., Li, X., and Zhang, S. (2021). Nanotechnology for Age-Related Macular Degeneration. Pharmaceutics, 13.","DOI":"10.3390\/pharmaceutics13122035"},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1080\/17425247.2021.1888925","article-title":"Nanotechnology: Revolutionizing the delivery of drugs to treat age-related macular degeneration","volume":"18","author":"Sharma","year":"2021","journal-title":"Expert Opin. Drug Deliv."},{"key":"ref_160","doi-asserted-by":"crossref","unstructured":"Galindo-Camacho, R.M., and Blanco-Llamero, C. (2022). Therapeutic Approaches for Age-Related Macular Degeneration. IJMS, 23.","DOI":"10.3390\/ijms231911769"},{"key":"ref_161","doi-asserted-by":"crossref","unstructured":"Paliwal, H., and Prajapati, B.G. (2023). Novel Approaches in the Drug Development and Delivery Systems for Age-Related Macular Degeneration. Life, 13.","DOI":"10.3390\/life13020568"},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"16769","DOI":"10.1039\/D4NR01917B","article-title":"Advanced nanomedicines for the treatment of age-related macular degeneration","volume":"16","author":"Kwon","year":"2024","journal-title":"Nanoscale"},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"683","DOI":"10.2174\/1567201820666230510100742","article-title":"Age-Related Macular Degeneration\u2014Therapies and Their Delivery","volume":"21","author":"Ponnusamy","year":"2024","journal-title":"Curr. Drug Deliv."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1208\/s12249-019-1474-0","article-title":"An in vitro assessment of thermo-reversible gel formulation containing sunitinib nanoparticles for neovascular age-related macular degeneration","volume":"20","author":"Bhatt","year":"2019","journal-title":"AAPS PharmSciTech"},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.ijpharm.2018.05.056","article-title":"Smart liposomal drug delivery for treatment of oxidative stress model in human embryonic stem cell-derived retinal pigment epithelial cells","volume":"548","author":"Behroozi","year":"2018","journal-title":"Int. J. Pharm."},{"key":"ref_166","doi-asserted-by":"crossref","unstructured":"Joseph, R.R., Tan, D.W.N., Ramon, M.R.M., Natarajan, J.V., Agrawal, R., Wong, T.T., and Venkatraman, S.S. (2017). Characterization of liposomal carriers for the trans-scleral transport of Ranibizumab. Sci. Rep., 7.","DOI":"10.1038\/s41598-017-16791-7"},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.2147\/IJN.S446425","article-title":"Topical Ophthalmic Liposomes Dual-Modified with Penetratin and Hyaluronic Acid for the Noninvasive Treatment of Neovascular Age-Related Macular Degeneration","volume":"19","author":"Sun","year":"2024","journal-title":"Int. J. Nanomed."},{"key":"ref_168","doi-asserted-by":"crossref","unstructured":"Chen, X., Liu, S., Chen, M., Ni, N., Zhou, R., Wang, Y., Xu, Y., Wang, Y., Gao, H., and Zhang, D. (2024). Novel therapeutic perspectives for wet age-related macular degeneration: RGD-modified liposomes loaded with 2-deoxy-D-glucose as a promising nanomedicine. Biomed. Pharmacother. Biomed. Pharmacother., 175.","DOI":"10.1016\/j.biopha.2024.116776"},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.drudis.2007.12.005","article-title":"Ophthalmic light sensitive nanocarrier systems","volume":"13","author":"Christie","year":"2008","journal-title":"Drug Discov. Today"},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.preteyeres.2018.11.001","article-title":"Transplantation of photoreceptors into the degenerative retina: Current state and future perspectives","volume":"69","author":"Gasparini","year":"2019","journal-title":"Prog. Retin. Eye Res."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.2217\/nnm-2018-0299","article-title":"Gold nanoparticles for multimodal high-resolution imaging of transplanted cells for retinal replacement therapy","volume":"14","author":"Chemla","year":"2019","journal-title":"Nanomedicine"},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"2205754","DOI":"10.1002\/smll.202205754","article-title":"Functional carbon quantum dots for ocular imaging and therapeutic applications","volume":"19","author":"Kumar","year":"2023","journal-title":"Small"},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1038\/eye.2015.64","article-title":"Sustained supplementation and monitored response with differing carotenoid formulations in early age-related macular degeneration","volume":"29","author":"Akuffo","year":"2015","journal-title":"Eye"},{"key":"ref_174","doi-asserted-by":"crossref","unstructured":"Obana, A., Gohto, Y., Nakazawa, R., Moriyama, T., Gellermann, W., and Bernstein, P.S. (2020). Effect of an antioxidant supplement containing high dose lutein and zeaxanthin on macular pigment and skin carotenoid levels. Sci. Rep., 10.","DOI":"10.1038\/s41598-020-66962-2"},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"121725","DOI":"10.1016\/j.ijpharm.2022.121725","article-title":"Liposomal sunitinib for ocular drug delivery: A potential treatment for choroidal neovascularization","volume":"620","author":"Tavakoli","year":"2022","journal-title":"Int. J. Pharm."},{"key":"ref_176","doi-asserted-by":"crossref","unstructured":"Malakouti-Nejad, M., Monti, D., Burgalassi, S., Bardania, H., Elahi, E., and Morshedi, D. (2024). A comparison between the effects of two liposome-encapsulated bevacizumab formulations on ocular neovascularization inhibition. Colloids Surf. B Biointerfaces, 234.","DOI":"10.1016\/j.colsurfb.2023.113708"},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.jconrel.2023.01.080","article-title":"Co-delivery of microRNA-150 and quercetin by lipid nanoparticles (LNPs) for the targeted treatment of age-related macular degeneration (AMD)","volume":"355","author":"Li","year":"2023","journal-title":"J. Control. Release"},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.actbio.2023.05.021","article-title":"Targeted long-term noninvasive treatment of choroidal neovascularization by biodegradable nanoparticles","volume":"166","author":"Yao","year":"2023","journal-title":"Acta Biomater."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.jconrel.2023.04.003","article-title":"Mesenchymal stem cell exosomes as nanotherapeutics for dry age-related macular degeneration","volume":"357","author":"Tang","year":"2023","journal-title":"J. Control. Release"},{"key":"ref_180","doi-asserted-by":"crossref","unstructured":"Krishnan, A., Sendra, V.G., Patel, D., Lad, A., Greene, M.K., Smyth, P., Gallaher, S.A., Herron, \u00da.M., Scott, C.J., and Genead, M. (2023). PolySialic acid-nanoparticles inhibit macrophage mediated inflammation through Siglec agonism: A potential treatment for age related macular degeneration. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1237016"},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1021\/acsnano.2c05447","article-title":"Repeated Topical Administration of 3 Nm Cerium Oxide Nanoparticles Reverts Disease Atrophic Phenotype and Arrests Neovascular Degeneration in AMD Mouse Models","volume":"17","author":"Badia","year":"2023","journal-title":"ACS Nano"},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"8819","DOI":"10.2147\/IJN.S217038","article-title":"Anti-angiogenic activity of bevacizumab-bearing dexamethasone-loaded plga nanoparticles for potential intravitreal applications","volume":"14","author":"Liu","year":"2019","journal-title":"Int. J. Nanomed."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1002\/jbm.a.36424","article-title":"Ocular implant containing bevacizumab-loaded chitosan nanoparticles intended for choroidal neovascularization treatment","volume":"106","author":"Badiee","year":"2018","journal-title":"J. Biomed. Mater. Res. Part A"},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1080\/02713683.2022.2053166","article-title":"Simultaneous Release of Aflibercept and Dexamethasone from an Ocular Drug Delivery System","volume":"47","author":"Rudeen","year":"2022","journal-title":"Curr. Eye Res."},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"105735","DOI":"10.1016\/j.ejps.2021.105735","article-title":"A grafted copolymer-based nanomicelles for topical ocular delivery of everolimus: Formulation, characterization, ex-vivo permeation, in-vitro ocular toxicity, and stability study","volume":"159","author":"Mehra","year":"2021","journal-title":"Eur. J. Pharm. Sci."},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.ejpb.2021.05.022","article-title":"Long-acting nanoparticle-loaded bilayer microneedles for protein delivery to the posterior segment of the eye","volume":"165","author":"Wu","year":"2021","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"101204","DOI":"10.1016\/j.jddst.2019.101204","article-title":"Production of dasatinib encapsulated spray-dried poly (lactic-co-glycolic acid) particles","volume":"53","author":"Chauhan","year":"2019","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1021\/acs.molpharmaceut.8b01319","article-title":"Fenofibrate-loaded biodegradable nanoparticles for the treatment of experimental diabetic retinopathy and neovascular age-related macular degeneration","volume":"16","author":"Qiu","year":"2019","journal-title":"Mol. Pharm."},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"3148","DOI":"10.1002\/jbm.a.35446","article-title":"Albuminated PLGA nanoparticles containing bevacizumab intended for ocular neovascularization treatment","volume":"103","author":"Varshochian","year":"2015","journal-title":"J. Biomed. Mater. Res. Part A"},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.ijbiomac.2021.09.069","article-title":"Sirolimus loaded chitosan functionalized poly (lactic-co-glycolic acid)(PLGA) nanoparticles for potential treatment of age-related macular degeneration","volume":"191","author":"Suri","year":"2021","journal-title":"Int. J. Biol. Macromol."},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"101879","DOI":"10.1016\/j.nantod.2023.101879","article-title":"Dark matter: Developing a new nanoantioxidant-based therapeutic system for the treatment of age-related macular degeneration","volume":"50","author":"Kwon","year":"2023","journal-title":"Nano Today"},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1097\/APO.0000000000000291","article-title":"Emerging therapies in neovascular age-related macular degeneration in 2020","volume":"9","author":"Samanta","year":"2020","journal-title":"Asia-Pac. J. Ophthalmol."},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"5864","DOI":"10.1167\/iovs.16-19952","article-title":"Administration of menadione, vitamin K3, ameliorates off-target effects on corneal epithelial wound healing due to receptor tyrosine kinase inhibition","volume":"57","author":"Rush","year":"2016","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"14","DOI":"10.3390\/jfb4010014","article-title":"Design and in vitro biocompatibility of a novel ocular drug delivery device","volume":"4","author":"Gooch","year":"2013","journal-title":"J. Funct. Biomater."},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"102394","DOI":"10.1016\/j.eclinm.2023.102394","article-title":"Safety and efficacy of ixoberogene soroparvovec in neovascular age-related macular degeneration in the United States (OPTIC): A prospective, two-year, multicentre phase 1 study","volume":"67","author":"Khanani","year":"2024","journal-title":"Eclinicalmedicine"},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.ophtha.2023.09.006","article-title":"Single Center Experience with Voretigene Neparvovec Gene Augmentation Therapy in RPE65 Mutation\u2013Associated Inherited Retinal Degeneration in a Clinical Setting","volume":"131","author":"Lorenz","year":"2024","journal-title":"Ophthalmology"},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1517\/13543784.2015.961601","article-title":"Drugs in Phase II clinical trials for the treatment of age-related macular degeneration","volume":"24","author":"Tolentino","year":"2015","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_198","unstructured":"Roche (2023, October 29). Roche Presents Positive Phase II Results for the First-Ever Eye Implant Demonstrating Sustained Delivery of a Biologic Medicine to Treat People with Neovascular Age-Related Macular Degeneration. Available online: https:\/\/www.roche.com\/investors\/updates\/inv-update-2018-07-26b."},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1136\/bjophthalmol-2018-313462","article-title":"Posterior segment drug delivery for the treatment of exudative age-related macular degeneration and diabetic macular oedema","volume":"103","author":"Wong","year":"2019","journal-title":"Br. J. Ophthalmol."},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.ajo.2022.02.019","article-title":"A randomized, double-masked, multicenter trial of topical acrizanib (LHA510), a tyrosine kinase VEGF-receptor inhibitor, in treatment-experienced subjects with neovascular age-related macular degeneration","volume":"239","author":"Poor","year":"2022","journal-title":"Am. J. Ophthalmol."},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1097\/IAE.0b013e3181a2f42a","article-title":"Preparation, characterization, and in vivo evaluation of nanoliposomes-encapsulated bevacizumab (avastin) for intravitreal administration","volume":"29","author":"Abrishami","year":"2009","journal-title":"Retina"},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1248\/bpb.b23-00066","article-title":"Potential of TAK-593 ophthalmic emulsion for the treatment of age-related macular degeneration","volume":"46","author":"Mori","year":"2023","journal-title":"Biol. Pharm. Bull."}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/60\/10\/1647\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:09:26Z","timestamp":1760112566000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/60\/10\/1647"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,8]]},"references-count":202,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2024,10]]}},"alternative-id":["medicina60101647"],"URL":"https:\/\/doi.org\/10.3390\/medicina60101647","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,8]]}}}